Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SZSE: 300255)
Health Care · Pharmaceuticals · CN
CN¥24.53
-10.01% today · -53.9% 1Y
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SZSE: 300255) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $3.35B and employs 1,194 people.
Over the last twelve months the share price has lost 53.9%, trading between 21.19 and 71.71.
Tweenvest scores Hebei Changshan Biochemical Pharmaceutical Co., Ltd. across four factors: quality 42/100, value 37/100, growth 0/100. Its strongest factor is quality.
300255 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.35B
- Revenue (TTM)
- $126.50M
- P/E
- —
- EPS
- -0.39
- Dividend yield
- —
- Beta (5Y)
- 0.34
- 52-week high
- CN¥71.71
- 52-week low
- CN¥21.19
- Avg volume (3M)
- —
- Shares outstanding
- 919.06M
- Employees
- 1,194
- Next earnings
- —
About Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. operates within China, focusing on the entire lifecycle of heparin-based pharmaceuticals – from their initial research and development to manufacturing and sales. Their products are primarily utilized for the treatment of cardiovascular and cerebrovascular diseases. The company offers a broad range of heparin compounds, including crude heparin sodium and refined heparin sodium raw materials. Their portfolio also features a variety of injectable heparin preparations, such as standard heparin sodium injections. Furthermore, they produce both the raw materials and finished injectable forms for several low molecular weight heparins, specifically low molecular weight heparin calcium, enoxaparin sodium, nadroparin calcium, and dalteparin sodium. Established in the year 2000, Hebei Changshan Biochemical Pharmaceutical Co., Ltd. is headquartered in Shijiazhuang, China.
- ISIN
- CNE1000016C2
- Founded
- 1992
- Listed since
- Aug 19, 2011
- Exchange
- Shenzhen Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,257.00 | +0.13% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $271.37 | +0.42% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $153.38 | +0.54% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.90 | -1.25% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.48 | -0.76% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.13 | +0.21% |
Figures last refreshed Aug 18, 2026.